Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.

Moshe Jakubowski1, Peter J McAllister, Zahid H Bajwa

  • 1Departments of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA Associate Neurologists of Southern Connecticut, Fairfield, CT, USA Dartmouth-Hitchcock Medical Center, Hanover, NH, USA.

Pain
|October 31, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

In Memoriam: Neil Raskin MD, FAHS, FAAN (1935-2026).

Headache·2026
Same author

Transcultural headache medicine: A framework for integrating cultural contexts into headache science and care - a call to action from the International Headache Society.

Cephalalgia : an international journal of headache·2026
Same author

Migraine as a primary care-sensitive condition: Building pathways to accessible care.

Cephalalgia : an international journal of headache·2026
Same author

Elucidating the nociceptive role of CGRP in migraine headache.

Brain : a journal of neurology·2026
Same author

A cross-sectional analysis of brain structure, pain behaviors, and mental health in persons with surgically confirmed endometriosis.

Communications biology·2025
Same author

Mapping Dural and Periosteal SV2C, a Botulinum Toxin A Receptor, in the Mouse.

Toxins·2025
Same journal

Efficacy and effectiveness of melatonin for the management of musculoskeletal pain: a systematic review and meta-analysis of placebo and active controlled trials.

Pain·2026
Same journal

Predictive socio-cultural factors of pain intensity, disability, and quality of life in patients with nonspecific musculoskeletal pain: a prospective cohort study.

Pain·2026
Same journal

Reward-induced endogenous pain inhibition scales with action-outcome certainty in humans.

Pain·2026
Same journal

Training alpha to treat pain: dissociable pathways to analgesia.

Pain·2026
Same journal

Neurophysiological and psychophysical mechanisms associated with immersive virtual reality-induced hypoalgesia: a systematic review.

Pain·2026
Same journal

Dissociable peripheral and central mechanisms of monoacylglycerol lipase inhibition on pain- and depression-related behaviors in a rat model of neuropathic pain.

Pain·2026
See all related articles

Botulinum toxin type A (BTX-A) injections effectively reduce migraine frequency in patients experiencing imploding or ocular headaches. Exploding headaches, however, were not improved by this treatment.

Area of Science:

  • Neurology
  • Pain Medicine
  • Medical Therapeutics

Background:

  • Migraine management traditionally relies on abortive medications.
  • Prophylactic treatments aim to decrease migraine attack frequency.
  • Botulinum Toxin Type A (BTX-A) injections are an established prophylactic approach for chronic migraine.

Purpose of the Study:

  • To identify neurological markers distinguishing migraine patients who benefit from BTX-A treatment.
  • To compare responders and non-responders based on their reported migraine symptoms.

Main Methods:

  • Prospective and retrospective analysis of 63 migraine patients undergoing BTX-A treatment (100 units, 21 injection sites).
  • Comparison of neurological symptoms between BTX-A responders and non-responders.

Related Experiment Videos

  • Statistical analysis of migraine days and symptom prevalence before and after treatment.

    • Main Results:

    • BTX-A significantly reduced migraine days by 95.3% in 39 responders, while 24 non-responders showed no change.
    • Common migraine symptoms (aura, photophobia, phonophobia, osmophobia, nausea, throbbing) were similar in both groups.
    • Non-responders predominantly reported 'exploding headaches' (pressure buildup), while responders described 'imploding headaches' (crushed/clamped sensation) or 'ocular headaches'.

    Conclusions:

    • The effectiveness of BTX-A in treating imploding and ocular headaches suggests involvement of extracranial innervation.
    • The lack of response to BTX-A for exploding headaches supports the hypothesis of intracranial pain mediation.
    • Patient-reported headache characteristics can serve as potential biomarkers for BTX-A treatment response in migraine.